Clinical Trial Update: B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BMCA-targeted CAR-T therapy in refractory/relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BMCA-targeted CAR-T

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN